LAXAI Life Sciences appoints Sripathy Venkatraman as CEO
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Upgrades 2025 full-year CDMO sales and margin outlook
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Subscribe To Our Newsletter & Stay Updated